PURPOSE: Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non-small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital-based Case-Control Surveillance Study, conducted in four US centers during 1976 to 2001. METHODS: Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months. RESULTS: The OR for lung cancer among ERT users was 1.0 (95%CI 0.8-1.4), and it was 1.0 (95%CI 0.7-1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non-significant increases for non-small cell types other than squamous, but there was no consistent pattern across duration of use. CONCLUSION: Our data do not support an increased risk of lung cancer among women who use ERT.
PURPOSE: Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in humannon-small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital-based Case-Control Surveillance Study, conducted in four US centers during 1976 to 2001. METHODS: Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months. RESULTS: The OR for lung cancer among ERT users was 1.0 (95%CI 0.8-1.4), and it was 1.0 (95%CI 0.7-1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non-significant increases for non-small cell types other than squamous, but there was no consistent pattern across duration of use. CONCLUSION: Our data do not support an increased risk of lung cancer among women who use ERT.
Authors: Cari L Meinhold; Amy Berrington de González; Elise D Bowman; Alina V Brenner; Raymond T Jones; James V Lacey; Christopher A Loffredo; Donna Perlmutter; Sara J Schonfeld; Glenwood E Trivers; Curtis C Harris Journal: Int J Cancer Date: 2011-03-15 Impact factor: 7.396
Authors: Louise A Brinton; Lauren Schwartz; Margaret R Spitz; Yikyung Park; Albert R Hollenbeck; Gretchen L Gierach Journal: Cancer Causes Control Date: 2012-02-25 Impact factor: 2.506
Authors: Ann G Schwartz; Roberta M Ray; Michele L Cote; Judith Abrams; Robert J Sokol; Susan L Hendrix; Chu Chen; Rowan T Chlebowski; F Allan Hubbell; Charles Kooperberg; JoAnn E Manson; Mary Jo O'Sullivan; Thomas Rohan; Marcia L Stefanick; Jean Wactawski-Wende; Heather Wakelee; Michael S Simon Journal: J Thorac Oncol Date: 2015-07 Impact factor: 15.609
Authors: Christina S Baik; Gary M Strauss; Frank E Speizer; Diane Feskanich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-25 Impact factor: 4.254
Authors: Jessica K Paulus; Wei Zhou; Peter Kraft; Bruce E Johnson; Xihong Lin; David C Christiani Journal: Lung Cancer Date: 2010-07-23 Impact factor: 5.705
Authors: Louise A Brinton; Gretchen L Gierach; Abegail Andaya; Yikyung Park; Arthur Schatzkin; Albert R Hollenbeck; Margaret R Spitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-05 Impact factor: 4.254
Authors: Joshua R Smith; Elizabeth Barrett-Connor; Donna Kritz-Silverstein; Deborah L Wingard; Wael K Al-Delaimy Journal: Menopause Date: 2009 Sep-Oct Impact factor: 2.953
Authors: Angela Cecilia Pesatori; Michele Carugno; Dario Consonni; Neil E Caporaso; Sholom Wacholder; Margaret Tucker; Maria Teresa Landi Journal: Int J Cancer Date: 2012-11-26 Impact factor: 7.396